Literature DB >> 6454771

Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone.

C H Pui, G A Burghen, W P Bowman, R J Aur.   

Abstract

We determined retrospectively the frequency and risk of hyperglycemia in 421 children with leukemia who had received L-asparaginase and prednisone as part of their remission induction therapy. Forty-one patients (9.7%) developed this complication, 39 within one week after the first dose of L-asparaginase. Hyperglycemia resolved in all patients and in 32 before the end of the four-week induction period. Age, obesity, and Down syndrome each had a significant bearing on the frequency of hyperglycemia. Children 10 years of age or older were more likely to develop the complication than were younger children. When more than one factor was present in a child, the risk of hyperglycemia increased significantly. A family history of diabetes mellitus also appeared related to an increased risk of hyperglycemia. Childhood leukemia patients with any of the risk factors identified here should be closely monitored for glucosuria while receiving prednisone and L-asparaginase for remission induction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454771     DOI: 10.1016/s0022-3476(81)80955-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  26 in total

1.  Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.

Authors:  Dror Koltin; Lillian Sung; Ahmed Naqvi; Stacey L Urbach
Journal:  Support Care Cancer       Date:  2011-11-08       Impact factor: 3.603

2.  Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis.

Authors:  M V Pokrovskaya; S S Aleksandrova; V S Pokrovsky; A V Veselovsky; D V Grishin; O Yu Abakumova; O V Podobed; A A Mishin; D D Zhdanov; N N Sokolov
Journal:  Mol Biotechnol       Date:  2015-03       Impact factor: 2.695

3.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.

Authors:  K Scott Baker; Kirsten K Ness; Julia Steinberger; Andrea Carter; Liton Francisco; Linda J Burns; Charles Sklar; Stephen Forman; Daniel Weisdorf; James G Gurney; Smita Bhatia
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

4.  Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs.

Authors:  Meghan C McCormick; Eleanor Sharp; Ramasubramanian Kalpatthi; James Zullo; Nursen Gurtunca; Jun Zhang; Robert Krafty; Sripriya Raman
Journal:  Pediatr Blood Cancer       Date:  2020-06-26       Impact factor: 3.167

Review 5.  Pharmacotherapeutic Considerations for Individuals with Down Syndrome.

Authors:  Erik Hefti; Javier G Blanco
Journal:  Pharmacotherapy       Date:  2017-01-13       Impact factor: 4.705

6.  Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.

Authors:  Amy M Linabery; Wenchao Li; Michelle A Roesler; Logan G Spector; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-10       Impact factor: 4.254

7.  Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.

Authors:  J R Roberson; H L Spraker; J Shelso; Y Zhou; H Inaba; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C-H Pui; S C Howard
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

8.  Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.

Authors:  Eric J Chow; Catherine Pihoker; Debra L Friedman; Stephanie J Lee; Jeannine S McCune; Claire Wharton; Christian L Roth; K Scott Baker
Journal:  Pediatr Blood Cancer       Date:  2012-10-05       Impact factor: 3.167

9.  Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia.

Authors:  Stefanie Lowas; Suman Malempati; Daniel Marks
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

10.  Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study.

Authors:  Hannah E Williams; Carrie R Howell; Wassim Chemaitilly; Carmen L Wilson; Seth E Karol; Vikki G Nolan; Matthew P Smeltzer; Daniel M Green; Matthew J Ehrhardt; Daniel A Mulrooney; Ching-Hon Pui; Melissa M Hudson; Leslie L Robison; Kirsten K Ness
Journal:  Cancer       Date:  2019-11-12       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.